Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 65. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome964
Zolbetuximab treatment in metastatic gastric cancer686
Hybrid EASL Congress 2023640
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology629
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis553
Mapping neuroimmune interactions in the gut548
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed497
2023 FDA approvals in gastroenterology and hepatology490
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa433
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection426
Western lifestyle, metaflammation and the cell of origin of colon cancer343
Nomenclature of HBV core protein-targeting antivirals322
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection297
Advancing nutrition science for global health294
The future of treating pancreatic exocrine insufficiency271
Digestive Disease Week 2022266
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health260
Black–White disparities across the colorectal cancer care continuum in the USA249
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis238
Large language models for clinical decision support in gastroenterology and hepatology233
Artificial intelligence and automation in endoscopy and surgery219
New understanding of hepatobiliary MRI214
Metastatic pancreatic cancer and the liver210
Lessons from incretin-based therapy in MASH and obesity202
Inflammatory bowel disease in pregnancy and breastfeeding196
A crucial Fusobacterium nucleatum clade in colorectal cancer195
Novel insights into chronic HBV infection183
Food as medicine in gastrointestinal cancer therapy182
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease179
The critical role of gut–brain signalling in eating behaviour and obesity173
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation171
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract168
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges168
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases165
Hepatocyte-derived biomarkers in alcohol-related cirrhosis156
Integrated systems approach to identify environmental factors in intestinal inflammation155
Implications of the evolving knowledge of the genetic architecture of MASLD152
Characterizing the genomic landscape of colorectal cancer152
Estimating dietary intake from human stool DNA141
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment141
HDCA ameliorates NAFLD in mice135
Probiotics for preterms: sharing complex decision-making134
The path to successful hepatitis C elimination in Spain132
Preventing the progression of cirrhosis to decompensation and death128
Medical therapy of paediatric inflammatory bowel disease127
Metabolic diseases in the East Asian populations124
Human intestinal B cells in inflammatory diseases119
SSRIs and depression: role of gut–brain communication113
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook106
Current and future colorectal cancer screening strategies103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease99
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management98
Proteases in intestinal health and disease93
Liver, ageing and disease91
Phase III results for first-line treatment for metastatic colorectal cancer88
NAFLD prevalence in older patients with T2DM88
ECCO’2488
GLP1R agonists in NAFLD: a promising therapy on the horizon82
Microbiota and colorectal cancer — controlling for confounders challenges associations82
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’80
Enteric nervous system transfers stress to the gut79
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance77
Author Correction: Hepatic immune regulation and sex disparities71
The future of pathology in gastroenterology and hepatology69
Transforming the landscape of liver cancer detection and care65
0.39992022514343